These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 33538758)
1. High prevalence of biochemical disturbances of chronic kidney disease - mineral and bone disorders (CKD-MBD) in a nation-wide peritoneal dialysis cohort: are guideline goals too hard to achieve? Weissheimer R; Bucharles SGE; Truyts CAM; Jorgetti V; Figueiredo AE; Barrett P; Olandoski M; Pecoits-Filho R; Moraes TP J Bras Nefrol; 2021; 43(2):173-181. PubMed ID: 33538758 [TBL] [Abstract][Full Text] [Related]
2. International variations in serum PTH and calcium levels and their mortality associations in peritoneal dialysis patients: Results from PDOPPS. Nitta K; Bieber B; Karaboyas A; Johnson DW; Kanjanabuch T; Kim YL; Lambie M; Hartman J; Shen JI; Naljayan M; Pecoits-Filho R; Robinson BM; Pisoni RL; Perl J; Kawanishi H Perit Dial Int; 2024 Jul; 44(4):275-286. PubMed ID: 38501163 [TBL] [Abstract][Full Text] [Related]
3. Achievements in CKD-MBD guidelines targets: is there a progress in the implementation practice? Spasovski G; Zdravkovska V; Zabzun M; Antarorov R; Ivanovski K; Janakievska P; Neskovski J; Karceva-Sarajlia E; Panova B; Petrovska T; Zulbeari L; Masin-Spasovska J; Taleska-Matovska N; Gelev S Int Urol Nephrol; 2012 Dec; 44(6):1791-8. PubMed ID: 22173961 [TBL] [Abstract][Full Text] [Related]
4. Prevalence of chronic kidney disease-mineral and bone disorder in incident peritoneal dialysis patients and its association with short-term outcomes. Chuang SH; Wong HC; Vathsala A; Lee E; How PP Singapore Med J; 2016 Nov; 57(11):603-609. PubMed ID: 26778726 [TBL] [Abstract][Full Text] [Related]
5. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients. Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436 [TBL] [Abstract][Full Text] [Related]
6. Investigation on maintenance hemodialysis patients with mineral and bone disorder in Anhui province, China. Tao S; Li X; Liu Z; Bai Y; Qian G; Wu H; Li J; Guo Y; Yang S; Chen L; Yang J; Han J; Ma S; Yang J; Yu L; Shui R; Jin X; Wang H; Zhang F; Chen T; Li X; Zong X; Liu L; Fan J; Wang W; Zhang Y; Shi G; Wang D Int Urol Nephrol; 2023 Feb; 55(2):389-398. PubMed ID: 35951256 [TBL] [Abstract][Full Text] [Related]
7. High alkaline phosphatase and low intact parathyroid hormone associate with worse clinical outcome in peritoneal dialysis patients. Chen Z; Zhang X; Han F; Xie X; Hua Z; Huang X; Lindholm B; Haarhaus M; Stenvinkel P; Qureshi AR; Chen J Perit Dial Int; 2021 Mar; 41(2):236-243. PubMed ID: 32363998 [TBL] [Abstract][Full Text] [Related]
8. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe]. Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391 [TBL] [Abstract][Full Text] [Related]
9. Profile of chronic kidney disease related-mineral bone disorders in newly diagnosed advanced predialysis diabetic kidney disease patients: A hospital based cross-sectional study. Ray S; Beatrice AM; Ghosh A; Pramanik S; Bhattacharjee R; Ghosh S; Raychaudhury A; Mukhopadhyay S; Chowdhury S Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S931-S937. PubMed ID: 28728874 [TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Dialysis Modality on Laboratory Parameters of Mineral Metabolism. Soohoo M; Obi Y; Rivara MB; Adams SV; Lau WL; Rhee CM; Kovesdy CP; Kalantar-Zadeh K; Arah OA; Mehrotra R; Streja E Am J Nephrol; 2022; 53(2-3):157-168. PubMed ID: 35226895 [TBL] [Abstract][Full Text] [Related]
11. Mineral and bone disorder in hemodialysis patients in the Tibetan Plateau: a multicenter cross-sectional study. Dang ZH; Tang C; Li GL; Luobu C; Qing D; Ma ZH; Qu JF; Suolang L; Liu LJ Ren Fail; 2019 Nov; 41(1):636-643. PubMed ID: 31269846 [No Abstract] [Full Text] [Related]
12. Optimal targets of chronic kidney disease-mineral and bone disorder markers for Chinese patients with maintenance peritoneal dialysis: a single-center retrospective cohort study. Chen L; Tang X; Zheng H; Wang H; Xia P; Wang Y; Zhao X; Zhou Z; Qiu L; Li X Ren Fail; 2022 Dec; 44(1):336-345. PubMed ID: 35380083 [TBL] [Abstract][Full Text] [Related]
13. [Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian Society of Nephrology (ÖGN)]. Cejka D; Wakolbinger-Habel R; Zitt E; Fahrleitner-Pammer A; Amrein K; Dimai HP; Muschitz C Wien Med Wochenschr; 2023 Oct; 173(13-14):299-318. PubMed ID: 36542221 [TBL] [Abstract][Full Text] [Related]
14. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Isakova T; Nickolas TL; Denburg M; Yarlagadda S; Weiner DE; Gutiérrez OM; Bansal V; Rosas SE; Nigwekar S; Yee J; Kramer H Am J Kidney Dis; 2017 Dec; 70(6):737-751. PubMed ID: 28941764 [TBL] [Abstract][Full Text] [Related]
15. Changes in Markers of Mineral and Bone Disorders and Mortality in Incident Hemodialysis Patients. Soohoo M; Feng M; Obi Y; Streja E; Rhee CM; Lau WL; Wang J; Ravel VA; Brunelli S; Kovesdy CP; Kalantar-Zadeh K Am J Nephrol; 2016; 43(2):85-96. PubMed ID: 26950688 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of prevalence, biochemical profile, and drugs associated with chronic kidney disease-mineral and bone disorder in 11 dialysis centers. Abrita RR; Pereira BDS; Fernandes NDS; Abrita R; Huaira RMNH; Bastos MG; Fernandes NMDS J Bras Nefrol; 2018; 40(1):26-34. PubMed ID: 29796575 [TBL] [Abstract][Full Text] [Related]
17. International variation in the management of mineral bone disorder in patients with chronic kidney disease: Results from CKDopps. Liabeuf S; McCullough K; Young EW; Pisoni R; Zee J; Reichel H; Pecoits-Filho R; Port FK; Stengel B; Csomor PA; Metzger M; Robinson B; Massy ZA Bone; 2019 Dec; 129():115058. PubMed ID: 31493530 [TBL] [Abstract][Full Text] [Related]
18. Status of Serum Calcium, Phosphate and Intact Parathyroid Hormone in Predialysis Chronic Kidney Disease Patients of Stage-3 to Stage-5 Compared To KDOQI Guideline. Hai AA; Rahman MM; Anwar MR; Miah OF; Latif A; Jalil ME; Razzak MA; Morshed AM; Mahmud H; Dowel FA Mymensingh Med J; 2021 Oct; 30(4):1031-1042. PubMed ID: 34605474 [TBL] [Abstract][Full Text] [Related]
19. Association between Hemodialysis Patient Outcomes and Compliance with KDOQI and KDIGO Targets for Mineral and Bone Metabolism. Djukanović L; Dimković N; Marinković J; Djurić Ž; Knežević V; Lazarević T; Ljubenović S; Marković R; Rabrenović V Nephron; 2016; 132(3):168-74. PubMed ID: 26914677 [TBL] [Abstract][Full Text] [Related]
20. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Souqiyyeh MZ; Shaheen FA Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]